

Review Article

Effect of Topical Administration of Fractions and Isolated Molecules from Plant Extracts on Skin Wound Healing: A Systematic Review of Murine Experimental Models

Mariáurea Matias Sarandy,¹ Fernanda Barbosa Lopes,² Sérgio Luis Pinto da Matta,¹ Marcus Vinicius Mello Pinto,³ Sirlene Souza Rodrigues Sartori,² Rômulo Dias Novaes,⁴ and Reggiani Vilela Golçalves²

¹Department of General Biology, Federal University of Viçosa, 35570-000 Viçosa, MG, Brazil

²Department of Animal Biology, Federal University of Viçosa, 35570-000 Viçosa, MG, Brazil

³Instituto Celulare, 25730-735 Petropolis, RJ, Brazil

⁴Institute of Biomedical Sciences, Department of Structural Biology, Federal University of Alfenas, 37130-000 Alfenas, MG, Brazil

Correspondence should be addressed to Reggiani Vilela Golçalves; reggysvilela@yahoo.com.br

Received 18 March 2016; Accepted 16 June 2016

Academic Editor: Chang-Shik Yin

Copyright © 2016 Mariáurea Matias Sarandy et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background and Purpose. Skin wound healing is a dynamic process driven by molecular events responsible for the morphofunctional repair of the injured tissue. In a systematic review, we analyzed the relevance of plant fractions and isolates on skin wound healing. By revising preclinical investigations with murine models, we investigated if the current evidence could support clinical trials. *Methods.* Studies were selected in the MEDLINE/PubMed and Scopus databases according to the PRISMA statement. All 32 identified studies were submitted to data extraction and the methodological bias was investigated according to ARRIVE strategy. *Results.* The studies demonstrated that plant fractions and isolates are able to modulate the inflammatory process during skin wound healing, being also effective in attenuating the oxidative tissue damage in the scar tissue and stimulating cell proliferation, neoangiogenesis, collagen synthesis, granulation tissue expansion, reepithelialization, and the wound closure rate. However, we identified serious methodological flaws in all studies, such as the high level of reporting bias and absence of standardized experimental designs, analytical methods, and outcome measures. *Conclusion.* Considering these limitations, the current evidence generated from flawed methodological animal studies makes it difficult to determine the relevance of herbal medicines to treat skin wounds and derails conducting clinical studies.

1. Introduction

The skin wound healing is a dynamic and complex process divided into three complementary stages: inflammatory, proliferative, and maturation. The inflammatory phase comprehends the intense leucocytes recruitment to the wound area, removal of cellular and extracellular matrix debris, and syntheses of regulatory molecules such as cytokines and chemokines [1, 2]. The proliferative phase progresses with an intense proliferation and migration of fibroblasts, endothelial cells,

and keratinocytes as well as formation of the granulation tissue (rich in type III collagen) and progressive reepithelialization [1–3]. At the maturation phase, type III collagen is gradually replaced by type I collagen, which originates more thicker and resistant collagen fibers [2–4].

It has been demonstrated that flaws on the leukocyte recruitment and function can impair the healing process due to reductions in the synthesis of regulatory molecules that drives the extracellular matrix assembly [5–7] and neoangiogenesis [8]. In this way, the development of drugs and

alternative treatments that favor the migration and cellular activity during the inflammatory and proliferation phases may enhance the skin wound repair.

Skin wounds represent a serious health problem worldwide frequently associated with high costs and inefficient treatments [9, 10]. The use of herbal drugs is opening a new perspective for the treatment of skin wounds, mainly in developing countries. Once herbal strategies represent a simple pharmacological option, 80% of the population uses herbal drugs in their health care [1]. Although several plant species are currently used in the popular medicine to treat skin wounds worldwide [11–14], the scientific evidence that supports this practice is scarce. Thus, determining the security and efficiency of herbal drugs is an urgent and challenging task, which is essential to develop new technologies and products potentially applied in wound care.

In general, the healing properties of plant products are related to specific secondary metabolites, especially tannins, saponins, flavonoids, and alkaloids [11, 47, 48]. Plant products present a broad spectrum of biological functions such as astringent, antimicrobial, antioxidant, and anti-inflammatory [49–54] functions, which has been systematically associated with the beneficial effects in stimulating the healing process [49, 52, 54]. Before extrapolation to the human condition, preclinical researches using animal models have been useful for testing the toxicological security and biological effects of plant fractions and isolated molecules with potential applicability in the treatment of skin wounds [11, 52].

Despite the increasing number of experimental trials in the last decade, few advances were observed in the treatment of skin wounds, especially in humans. Considering that studies using animal models are conceived to support clinical investigations, there is a clear limitation in translating the findings obtained from animal models of wound healing to the human context. Considering that herbal drugs are extensively used in the popular medicine, we still do not know where the gap is that hinders the implementation of experimental findings for the development of innovations and technologies potentially useful in the clinical management of skin wounds. Thus, we systematically revised preclinical studies with murine models that investigated the effects of plant fractions and isolated molecules on the treatment of skin wounds. Beyond determining the relevance of plant derivatives in the skin repair, we analyzed the methodological quality of all preclinical studies identified, especially considering that the quality of evidence generated from flawed methodological studies could compromise the generalizability of the findings and derail conducting clinical studies.

2. Materials and Methods

2.1. Search Strategy. Research papers that investigate the action of plant fractions and isolated molecules in murine models of skin wound healing, published until 09/04/2015 (15:05:23), were recovered and independently analyzed by three researchers (FBL, MMS, and RVG). The search strategy was constructed by four components: “animals (filter),” “injury (wounds),” “organ (skin),” and “plants extract (isolates and fractions).” The filters were developed from PubMed

database according to the hierarchical distribution of Medical Subject Headings [MeSH Terms]. A standardized search filter for animal studies was applied in PubMed database [55]. The same search strategy was adapted and used to recover studies in the Scopus platform. The standard animal filter provided by Scopus was used. The complete search strategy is described in Table S1 in Supplementary Material available online at <http://dx.doi.org/10.1155/2016/4916068>. Language restrictions were applied to recover only articles in English, Spanish, and Portuguese.

2.2. Selection Strategy. An initial selection based on title and abstract [TIAB] was independently conducted by the researchers (FBL, MMS, and RDN). Duplicate studies were removed and only studies investigating the effect of fractions and isolated molecules from plant extracts in murine models of skin wound healing were considered. After the initial search, all relevant studies were recovered in full text and evaluated by eligibility criteria. Works containing unrefined extracts, commercial isolates, *in vitro* assays, humans, nontraumatic injuries, other animal models, first intention wounds, metabolic diseases associates, and secondary studies (i.e., letter to the editor, note, review, and editorial) were excluded (Figure 1).

2.3. Data Extraction. Data were extracted and tabulated in a descriptive way (Tables 1(a), 1(b), 2(a), and 2(b)). The characteristics investigated were publication characteristics (author, title, publication year, and country); research methods (control group, randomization, experimental procedures, and blind evaluation of the results); experimental model (animal, number of animals, sex, age, weight, species, acclimation period, animal’s housing, number of animals per cage and experimental groups, food supply, temperature, and light cycle); plants (plant’s species, isolates, fractions, dose, toxicity test, exotic/native plant, popular name, utilized part of the plant, and popular indication); wounds description (wound area, measurement interval, and treatment duration) (Tables 1(a), 1(b), 2(a), and 2(b)). In a comprehensive approach, ethnobotanical/ethnopharmacological aspects were also investigated as follows: plant’s species investigated (geographic distribution and existence or not of bioprospecting), popular indication, and reports of toxicity tests (Figure 2).

2.4. Analysis of Bias. The articles quality was analyzed by the criteria described on the ARRIVE platform (Animal Research: Reporting of *In Vivo* Experiments). These criteria are based on short descriptions that indicate essential characteristics of all studies with animal models, such as theoretical and methodological basis, research objective, refinement of the analytical methods, statistical design, sample calculations, and measure outcomes [15]. Recently there has been an increasing interest in the systematic reviews of research involving animals [16]. Considering the purpose of the systematic review on evaluating important aspects of the referenced publications, we built a table summarizing all the aspects investigated as well as their relevance, describing positive and negative characteristics of the recovered studies (Tables 2(a) and 2(b)).

TABLE 1: (a) Description of the main characteristics of the studies with fractions obtained from plant extracts. (b) Description of the main characteristics of the studies with isolated molecules from plant extracts.

Reference	Country	Animal strain	Animal number	Sex	Age	Weight	Experimental groups	Animal number per group	Numbers of animals per box	Treatment control group	Plant species	Native/exotic	Used parts	Fractions	Dose	Popular indication	Wound area	Measurement interval	Wound area calculation	Treatment time
Bastos et al., 2011 [15]	Brazil	Wistar rats	12	♂	4 mo	300–320 g	4	3	1	Miconazole and nontonic cream	<i>Piper hayneanum</i> (Piperaceae)	?	L	[CHCl ₃ -EtOAc 1:1 (haulm, A) and CHCl ₃ -MeOH 1:1 (routs, B)]	?	Anti-inflammatory, infectious skin diseases and healing, wounds, hematoma, and ecchymosis	6 mm ²	Daily	?	15 days
Shukla et al., 1999 [16]	India	Sprague Dawley rats	?	♂	?	200–220 g	3	?	1	Saline solution	<i>Centella asiatica</i> (Apiaceae)	?	?	Asiaticoside	20 µL of 0.2%	Healing activity	8 mm ²	7/7 days	?	14 days
Muralidhar et al., 2011 [17]	India	Wistar rats	42	?	?	150–200 g	7	6	?	Ointment base	<i>Butea monosperma</i> (Fabaceae)	N	Sb	BENFR; benzene fraction, CHLFR; chloroform fraction, and ACEFR; acetone fraction	200 mg/kg	Antitumor, antiulcer, antifungal, and antidiarrheal activities	500 mm ²	4/4 days	?	16 days
Süntar et al., 2013 [18]	Turkey	Sprague Dawley rats	?	♂	?	160–180 g	?	6	?	Ointment base	<i>Helichrysum graveolens</i> (Asteraceae)	N	F	Hg-hexane; Hg-CH ₂ Cl ₂ ; Hg-EtOAc; Hg-BuOH; Hg-R-H ₂ O; Hg-Fr.Bi; Hg-Fr.B2; Hg-Fr.B3; Hg-Fr.A; Hg-Fr.B; and Hg-Fr.C	0.5 g	Antimicrobial, antioxidant, anti-inflammatory, sedative, antidiabetic, and cytotoxic activities	5 mm ²	Daily	Reduction in wounded area, using AutoCAD program	12 days
Mekonnen, et al., 2013 [19]	Ethiopia	Swiss mice/Wistar rats	24	?	8–10 wk/3–5 mo	30–40 g/180–200 g	4	6	1	Sodium carboxyl methyl cellulose xerogel and nitrofurazone	<i>Kalanchoe peltiana</i> (Crassulaceae)	N	L	Methanolic and chloroform fractions were 16%, 8.76%, 75%, and 5.6%, respectively	?	Wound healing, hemorrhoids, and antibacterial activities	312 mm ²	Daily	Wound area on day 0 – wound area on day n/wound area on day 0 × 100	10 days
Pieters et al., 1995 [20]	Belgium	Wistar rats	?	♀	?	250–300 g	20	2	1	Not treated	<i>Croton</i> spp. (Euphorbiaceae)	E	Lx	Polyphenolic; PEG ointment, PEG 400 10%	0.5 mL/2x day	Wound healing	3 cm	Daily	?	18 days

(a)

(a) Continued.

Reference	Country	Animal strain	Animal number	Sex	Age	Weight	Experimental groups	Animal number per group	Numbers of animals per box	Treatment control group	Plant species	Native/exotic	Used parts	Fractions	Dose	Popular indication	Wound area	Measurement interval	Wound area calculation	Treatment time
Korkina et al., 2007 [21]	Italy	Wistar rats	40	♂	?	350–400 g	5	10	?	Saline solution	<i>Syringa vulgaris</i> (Oleaceae)	N	F	Two phenylpropanoid glycosides: verbascoside and teupolioside	100 µL (0.2 mg/mL)	Wound healing, anti-inflammatory, antirheumatic, antipyretic, and antifungal activities	2.25 cm ²	4/4 days	The recorded wounds were measured by planimetry using special computer program	8 days
Bigoniya et al., 2013 [22]	India	Wistar rats	30	♂	?	175 ± 10 g	5	6	?	Vehicle (not related)	<i>Euphorbia hirta</i> (Euphorbiaceae)	N	Wp	Flavonoid fraction (EHTF)	?	Antimicrobial, antifungal, antiviral, anti-inflammatory, antiarthritic, and antioxidant activities	500 mm ²	4/4 days	?	20 days
Lodhi et al., 2011 [23]	India	Wistar rats	30	♂♀	?	150–200 g	5	6	1	Not treated	<i>Martynia annua</i> (Martyniaceae)	N	L	<i>M. annua</i> fraction: MAF-A, MAF-B, and MAF-C	?	?	500 mm ²	2/2 days	% Wound contraction = healed area/total wound area × 100	20 days
Tabandeh et al., 2013 [24]	Iran	Wistar rats	60	♂	?	200 ± 50 g	4	15	?	Saline solution	<i>Silybum marianum</i> (Asteraceae)	E	?	Flavonoid silybinin (SB)	10% and 20% SB powder	Hepatoprotective and liver regenerating activities	1 cm	Daily	?	30 days
Sonmez et al., 2015 [25]	Turkey	Wistar rats	24	♂	?	180–260 g	3	8	?	Saline solution	<i>Solanum tuberosum</i> (Solanaceae)	?	?	Polysaccharide hemostat (APH)	3 mg of wheat meal in group 2 and 3 mg of APH in powder form	?	2 × 2 × 2 cm	3, 7, and 14 days	Percentage of contraction = [100 - (total wound area on the 14th day/total wound area on the 3rd day) × 100]	14 days

(a) Continued.

Reference	Country	Animal strain	Animal number	Sex	Age	Weight	Experimental groups	Animal number per group	Numbers of animals per box	Treatment control group	Plant species	Native/exotic	Used parts	Fractions	Dose	Popular indication	Wound area	Measurement interval	Wound area calculation	Treatment time
Karadas et al., 2012 [26]	Turkey	Wistar rats	12	♂	?	200–250 g	2	12 and 8	?	Not treated	<i>Bellis perennis</i> (Asteraceae)	E	F	n-Butanol fraction	?	Activities in sore throat, headache, eczema, skin boils, and gastritis	4 mm ²	1, 5, 10, and 30 days	Percentage of wound area = wound area in day/wound area in the first day × 100; 30 days	30 days
Choi et al., 2001 [27]	Korea	Hairless mice	10	♂	?	?	2	10	?	Vehicle (not related)	<i>Aloe vera</i> (Liliaceae)	?	?	Glycoprotein fraction named GIGIMID2	Gentamicin 0.1%, every day	Wound healing, thermal injury healing, anti-inflammation, and immunomodulation activities	154 mm ²	Daily	? %	8 days
Parente et al., 2011 [28]	Brazil	Wistar rats	36	♀	60 days	160–190 g	2	18 and 6	1	Distilled water	<i>Calendula officinalis</i> (Asteraceae)	E	F	DCF: dichloromethane fraction at 1%; HCF: hexane fraction at 1%	?	Anti-inflammatory, first-degree burns, and skin rashes activities	1 cm	4, 7, and 14 days	? %	14 days
Olughuyiro et al., 2010 [29]	Nigeria	Wistar rats	16	♂	?	250–300 g	2	4	1	Gentamicin and saline solution	<i>Flabellaria paniculata</i> (Malpighiaceae)	N	L	Chloroform fraction and aqueous fraction	100 mg/mL	Activities in skin infections, wounds and sores, and dysentery	2 × 2 cm	7, 12, 14, and 18 days	? %	18 days
Süntar et al., 2010 [30]	Turkey	Sprague-Dawley rats/Swiss mice	?	♂	?	160–180 g/20–25 g	9	6	?	Not treated	<i>Sambucus ebulus</i> (Caprifoliaceae)	N	L	Polyamide column fractions from the methanolic extract (Fr A, B, C, D, and E)	0.5 g	Hemorrhoids, rheumatic pain, treating burns, infectious wounds, edema, eczema, urticarial, and inflammations	5 mm ²	2/2 days	Wound contraction was calculated as percentage of the reduction in wounded area	12 days
Kim et al., 2013 [31]	Korea	Hairless mice	10	♀	2 mo	?	2	5	?	Matriigel solution	<i>Panax ginseng</i> (Araliaceae)	?	L	Ginsenoside Rd	10 mL	Strengthening immune system and atherosclerosis activities	?	3/3 days	? %	9 days

(a) Continued.

Reference	Country	Animal strain	Animal number	Sex	Age	Weight	Experimental groups	Animal number per group	Numbers of animals per box	Treatment control group	Plant species	Native/exotic	Used parts	Fractions	Dose	Popular indication	Wound area	Measurement interval	Wound area calculation	Treatment time
Chaudhuri et al., 2006 [32]	India	Wistar rats	30	♂♀	?	180–250 g	5	6	?	Soft paraffin (85%), cetosteryl alcohol (5%), hard paraffin (5%), and wool fat (5%)	<i>Terminalia arjuna</i> (Combretaceae)	N	Sb	Fraction I hydroalcohol	0.5 g	Diuretic, cooling, aphrodisiac, expectorant, antihypertensive, urinary astringent, antioxidant, and antibacterial activities	4 cm ²	2/2 days	?	16 days
										Fraction II phytoconstituents extraction of tannins				Fraction III consisted of saponins						
Swamy et al., 2006 [33]	India	Wistar rats	24	♂♀	?	150–200 g	4	6	?	Framycetin ointment	<i>Embelia ribes</i> (Myrsinaceae)	?	L	Embelin	4 mg/mL of 0.2% sodium alginate gel	Anti-inflammatory to relieve rheumatism and fever activities	500 mm ²	4/4 days	?	16 days
Hernandes et al., 2010 [34]	Brazil	Wistar rats	15	♂	?	180–200 g	3	5	1	Ointment base	<i>Stryphnodendron adstringens</i> (Fabaceae)	?	Sb	EIOAc fraction	?	Antioxidant, cicatrizing, and anti-inflammatory activities	7 mm ²	4, 7, and 10 days	?	10 days
Sidhu et al., 1999 [35]	USA and India	Sprague Dawley rats	?	♂	?	250–300 g	4	?	1	Vehicle PBS	<i>Arnebia nobilis</i> (Boraginaceae)	N	?	Arnebin-1 (5,8-dihydroxy-2-(9-b-b-dimethylaryoxy-49-methylpent-3-enyl)-1,4-naphthoquinone	?	?	8 mm ²	Daily	?	11 days
Paramesha et al., 2015 [36]	India	Wistar rats	18	?	?	150–200 g	3	6	?	Sodium alginate	<i>Carthamus tinctorius</i> (Asteraceae)	N	L	Dehydrobietyllamine of <i>C. tinctorius</i> L., var. <i>Annigeri-2</i>	50 g to get 0.2% (w/w) ointment gel	Laxative, appetizer, and diuretic also useful in urorthen and ophthalmopathy activities	?	4/4 days	?	16 days
Nageppan et al., 2012 [37]	Malaysia	Sprague Dawley rats	84	♀	?	200–250 g	7	12	1	Not treated	<i>Murraya koenigii</i> (Rutaceae)	N	L	Carbazole alkaloids mahanine (1) (0.40%) (C ₂₃ H ₂₅ NO ₂), mahanibicine (2) (0.24%) (C ₂₃ H ₂₅ NO), and mahanimbine (3) (0.66%)	Mahanine (1) (0.40%), (0.40%) (2) (0.24%), and (3) (0.66%) (w/w)	Stimulants, tonics, treating influenza, fever, and bronchial asthma activities	8 mm ²	Daily	% of wound contraction = $\frac{\text{Ø of wound area} - \text{Ø of unhealed w.a./diameter of w.a.}}{\text{wound area}} \times 100\%$	18 days

(a) Continued.

Reference	Country	Animal strain	Animal number	Sex	Age	Weight	Experimental groups	Animal number per group	Numbers of animals per box	Treatment control group	Plant species	Native/exotic	Used parts	Fractions	Dose	Popular indication	Wound area	Measurement interval	Wound area calculation	Treatment time
Qu et al., 2013 [38]	China	Sprague Dawley rats	54	♂	?	200–220 g	9	6	1	Vaseline	<i>Amorpha fruticosa</i> (Fabaceae)	N	Fr	6a,12a-dehydroamorphin, D-3-O-methyl-chiro-inositol, Kaempferol-3-glucoside, 7,4'-di-O-methyl-7,4'-dihydroxymundone, tetromethoxyflavone, dehydrosermundone, tephrosin, 7,4'-dimethoxyisoflavone	?	?	500 mm ²	2/2 days	Percent wound contraction = (original wound area – unhealed area)/original wound area × 100%	22 days

(b)

References	Country	Animal strain	Animal number	Sex	Age	Weight	Experimental groups	Animal number per group	Numbers of animals per box	Treatment control group	Plant species	Native/exotic	Used parts	Isolated	Dose	Popular indication	Wound area	Measurement interval	Wound area calculation	Treatment time
Chosh et al., 2012 [39]	India	Wistar rats/Swiss albino mice	36	♂	?	150–180 g/20–25 g	6	6	?	Ointment base	<i>Pedicularis titymaloides</i> (Euphorbiaceae)	N	L	2-(3,4-Dihydroxy-phenyl)-5,7-dihydroxy-chromen-4-one, 1, 2-tetradecanediol, and 1-(hydrogen sulfate)	50 mg	Antiviral, antibacterial, antihemorrhagic, antitumor, abortive, and anti-inflammatory activities	500 mm ²	3/3 days	(%) wound contraction 1/4 (initial × final wound area) × 100	21 days
Mukherjee et al., 2013 [40]	India	Swiss albino mice/Wistar rats	?	?	?	18–20 g/150–180 g	10	?	?	Ointment base and povidone iodine	<i>Shorea robusta</i> (Diptero-carpaceae)	N	L	Compound I: bioactive bergenia and compound II: triterpene ursolic acid	0.025 g of isolated compounds I and 2 mixed with 10 g ointment base	Wounds and burn healing	6 cm	3/3 days	Two-day inter-val/(wound area on day 0 × wound area on day n)/wound area on day 0 × 100	?
Melo et al., 2011 [41]	Brazil	Swiss mice	30	♀	12 wk	45.0 ± 2.0 g	4	?	1	NaCl	<i>Crapylia mollis</i> (Leguminosaceae)	N	S	Cramoll 1,4 lectin	100 g/mL	?	0.5 cm	2, 7, and 12 days	$A = \pi \times R \times r$	12 days

(b) Continued.

References	Country	Animal strain	Animal number	Sex	Age	Weight	Experimental groups	Animal number per group	Numbers of animals per box	Treatment control group	Plant species	Native/exotic	Used parts	Isolated	Dose	Popular indication	Wound area	Measurement interval	Wound area calculation	Treatment time
Pieters et al., 1995 [20]	Belgium	Wistar rats	40	♂	?	250–300 g	20	2	1	Not treated	<i>Croton</i> spp. (Euphorbiaceae)	E	Lx	3',4'-O-Dimethylcedrusin, taspine hydrochloride	0.5 mL/2x day	Wound healing activities	3 cm	Daily	?	18 days
Ahamed et al., 2008 [42]	India	Wistar rats	24	♂♀	?	240–250 g	4	6	6	Tween 80	<i>Grewia tiliifolia</i> (Tiliaceae)	N	Sb	Gulonic acid γ -lactone (GAGL)	50 mg/1x day	Burns, skin diseases, inflammation, diarrhea and pruritus, chronic wounds, and gastric ulcers	?	4/4 days	?	16 days
Zyuz'kov et al., 2012 [43]	Russian	?/mice	136	♂	2 mo	22–24 g	6	?	?	Water	<i>Aconitum baikalensis</i> (Ranunculaceae)	?	?	Songorine, napelline, hypaconitine, 12-epinapelline N-oxide, and mesaconitine	30 mL	?	10 × 10 mm	Daily	?	16 days
Singh et al., 2005 [44]	India	Wistar rats	20	♂♀	?	150–200 g	5	6	?	Tragacanth	<i>Elephantopus scaber</i> (Asteraceae)	N	L	Deoxyelephantopin	50 mg	Dysuria, diarrhea, dysentery, stomach pain; eczema and ulcers, and wound healing	500 mm ²	4/4 days	?	14 days
Sharath et al., 2010 [45]	India	Wistar rats	?	♂♀	?	200–250 g	2	5	?	Nitrofurazone	<i>Bacopa monnieri</i> (Scrophulariaceae)	N	?	Bacoside-A	200 mg	Laxative, ulcers, anemia, leucoderma, and scabies	500 mm ²	4/4 days	?	16 days
Vidya et al., 2012 [46]	India	Wistar rats	30	?	?	160–200 g	4	6	?	Nitrofurazone	<i>Entada pursaetha</i> (Mimosaceae)	N	S	Entadamide, phascolodin, and entagenic acid	?	Cancer, dropsy; eye diseases, wounds, snake bite, respiratory problems, and antibacterial	500 mm ²	4/4 days	?	16 days

Ad: adults; wk: week; mo: month; d: days; ♂: male; ♀: female; N: native; E: exotic; L: leaves; F: flowers; Sb: stem bark; S: seed; Wp: whole plant; Fr: fruits; Lx: latex; ? : not related.

TABLE 2: (a) Main parameters analyzed in the studies demonstrating the action of fractions from plants in the treatment of skin wounds in murine models. (b) Main parameters analyzed in the studies demonstrating the action of isolated molecules from plants in the treatment of skin wounds in murine models.

Reference	Wound closure analysis	Reepithelialization analysis	Oxidative stress	Granulation tissue fill	Tensile strengths
(a)					
Bastos et al., 2011	?	Fractions A and B: moderated 9 days Fractions A and B: 100% 15 days	?	After 15 days in the treated rats, the wound healing process by stimulating different biological events such as network of fibrin, epithelialization, granulation tissue, neovascularization, and wound contraction	?
Shukla et al., 1999	?	?	<i>Increased:</i> Superoxide dismutase (35%), catalase (67%), and glutathione peroxidase (49%) <i>Reduced:</i> Glutathione (17%)	?	?
Muralidhar et al., 2011	Petroleum ether fraction: (86.83 ± 0.87%) 16 days Benzene fraction: (86.67 ± 0.67%) 16 days Chloroform fraction: (88.0 ± 0.57%) 16 days Acetone fraction: (96.0 ± 0.37%) 16 days Control: (85.17 ± 0.79%) 16 days	<i>Epithelialization in days</i> Petroleum ether fraction: 21.17 ± 0.48% Benzene fraction: 21.67 ± 0.42% Chloroform fraction: 21.83 ± 0.48% Acetone fraction: 16.67 ± 0.42% Control: 22.0 ± 0.37%	?	<i>Hydroxyproline content (µg/mg)</i> Petroleum ether fraction: 21.57 ± 0.21 Benzene fraction: 20.96 ± 0.08 Chloroform fraction: 21.84 ± 0.08 Acetone fraction: 23.50 ± 0.17 Control: 21.48 ± 0.17	Petroleum ether fraction: 155.83 ± 2.26 g Benzene fraction: 151.0 ± 2.59 g Chloroform fraction: 163.33 ± 1.33 g Acetone fraction: 212.83 ± 2.02 g Control: 147.33 ± 1.23 g

(a) Continued.

Reference	Wound closure analysis	Reepithelialization analysis	Oxidative stress	Granulation tissue fill	Tensile strengths
	Wound area (mm^2) \pm SEM (contraction%) in 12 days Hg-MeOH: 0.96 ± 0.30 (65.71%) Hg-Hexane: 2.37 ± 0.11 (15.36%) Hg-CH ₂ Cl ₂ : 2.35 ± 0.29 (16.07%) Hg-EtOAc: 1.47 ± 0.32 (47.50%) Hg-BuOH: 1.74 ± 0.48 (37.86%) Hg-R-H ₂ O: 2.63 ± 0.17 (6.07%) Hg-Fr.A: 2.20 ± 0.39 (20.29%) Hg-Fr.B: 1.65 ± 0.09 (40.22%) Hg-Fr.C: 1.83 ± 0.14 (33.69%) Control: 2.76 ± 0.30 (6.44%)	Tissues treated with Hg-MeOH, Hg-EtOAc, and Hg-Fr.B demonstrated good wound recovery with faster reepithelialization compared to the other groups tested		Hydroxyproline content ($\mu\text{g}/\text{mg}$) Hg-MeOH: 26.3 ± 1.0 Hg-Hexane: 18.5 ± 2.1 Hg-CH ₂ Cl ₂ : 19.7 ± 1.9 Hg-EtOAc: 31.2 ± 0.9 Hg-BuOH: 15.6 ± 1.8 Hg-R-H ₂ O: 13.3 ± 1.8 Hg-Fr.A: 15.4 ± 1.2 Hg-Fr.B: 25.5 ± 1.2 Hg-Fr.C: 16.3 ± 1.9 Control: 8.9 ± 2.1	Hg-MeOH: 30.11% Hg-Hexane: 17.5% Hg-CH ₂ Cl ₂ : 15.2% Hg-EtOAc: 28.5% Hg-BuOH: 25.8% Hg-R-H ₂ O: 11.6% Hg-Fr.A: 13.9% Hg-Fr.B: 25.2% Hg-Fr.C: 21.3% Control: 5.8%
Süntar et al., 2013			?		
	Wound contraction in 12 days Chloroform: xerogel: 77.517 ± 1.88 , 5%: (79.91 ± 1.74) , and 10%: (82.63 ± 1.74) Methanol: simple ointment: (86.21 ± 1.5) , 5%: (90.86 ± 0.21) , and 10%: (92.09 ± 2.00) Control: (96.63 ± 0.32)	Epithelialization in days Chloroform: xerogel: (17.83 ± 0.30) , 5%: (17.16 ± 0.60) , and 10%: (16.83 ± 0.65) Methanol: simple ointment: (17.33 ± 0.33) , 5%: (15.66 ± 0.21) , and 10%: (15.33 ± 0.66) Positive control: (14.00 ± 0.44)	?	Hydroxyproline content ($\mu\text{g}/\text{mg}$) Chloroform: xerogel: (3.01 ± 0.46) , 5%: (5.83 ± 0.79) , and 10%: (7.08 ± 2.08) Methanol: simple ointment: (3.29 ± 0.66) , 5%: (11.01 ± 0.53) , and 10%: (15.33 ± 0.66) Control: (12.57 ± 2.59)	Chloroform: xerogel: 190.83 ± 15.62 g (14.26%), 5%: 238.33 ± 22.86 g (24.89%), and 10%: 265.00 ± 33.04 g (38.86%) Methanol: simple ointment: 201.50 ± 10.05 g (20.65%), 5%: 322.00 ± 23.63 g (59.80%), and 10%: 336.83 ± 28.39 g (67.16%) Control: 402.33 ± 30.26 g
Mekonnen et al. 2013					
	PEG ointment: (70%) 15 days PEG 400 10%: (80%) 15 days Polyphenolic fraction from dragon's blood in H ₂ O: (90%) 15 days Control: (60%) 15 days	PEG ointment: ++ (15 days) PEG 400 10%: ++ (15 days) Polyphenolic fraction from dragon's blood in H ₂ O: ++ (15 days) Control: + (15 days)	?	Crust presence PEG ointment: after 4 days PEG 400 10%: after 5 days Polyphenolic fraction from dragon's blood in H ₂ O: after 1 day Control: after 3 days	
Pieters et al., 1995					

(a) Continued.

Reference	Wound closure analysis	Reepithelialization analysis	Oxidative stress	Granulation tissue fill	Tensile strengths
			<i>Lipid peroxidation</i>		
			Both verbascoside 56% (7,4 ± 0,6%)		
			Both verbascoside 97% (5,8 ± 0,4%)		
			Teuplioside 70% (12,0 ± 0,7%)		
			Teuplioside 97% (9,4 ± 0,6%)		
			Control: (10,3 ± 1,0)		
			<i>Glutathione (GST)</i>		
			Both verbascoside 56% (3,0 ± 1,3%)		
			Both verbascoside 97% (5,1 ± 1,3%)	?	?
			Teuplioside 70% (3,4 ± 1,3%)		
			Teuplioside 97% (5,9 ± 1,2%)		
			Control: (3,6 ± 1,3%)		
			<i>Superoxide dismutases</i>		
			Both verbascoside 56% (2,5 ± 0,1%)		
			Both verbascoside 97% (2,2 ± 0,1%)		
			Teuplioside 70% (3,1 ± 0,3%)		
			Teuplioside 97% (1,0 ± 0,1%)		
			Control: (4,5 ± 0,5%)		
			<i>Vehicle control: catalase (0,46 ± 0,02%); SOD (1,15 ± 0,12%), and total protein (2,60 ± 0,06%)</i>		
			<i>EHTF 200: catalase (0,45 ± 0,03%), SOD (1,16 ± 0,06%), and total protein (2,69 ± 0,07%)</i>		
			<i>EHTF 400: catalase (0,52 ± 0,09%), SOD (2,63 ± 0,15%), and total protein (3,34 ± 0,05%)</i>		
			<i>EHTF 600: catalase (0,75 ± 0,19%), SOD (5,06 ± 0,09%), and total protein (4,02 ± 0,03%)</i>		
				<i>Hydroxyproline content</i>	
				EHTF 200 (15,89 ± 1,28%)	
				EHTF 400 (17,89 ± 2,26%)	?
				EHTF 600 (24,14 ± 2,23%)	
				Control (16,09 ± 1,35%)	
Korkina et al., 2007	Both verbascoside 56% (46,29 ± 12,21%) 8 days Both verbascoside 97% (124,29 ± 31,23%) 8 days Teuplioside 70% (78,39 ± 21,75%) 8 days Teuplioside 97% (98,45 ± 24,26%) 8 days Control (150,16 ± 65,46%) 8 days	?			
Bigoniya et al., 2013	EHTF 200 (71,01 ± 4,25%) 16 days EHTF 400 (69,98 ± 3,34%) 16 days EHTF 600 (6,02 ± 0,79%) 16 days Control (71,65 ± 3,21%) 16 days	EHTF 200 (19,66 ± 2,85%) EHTF 400 (19,50 ± 2,63%) EHTF 600 (17,50 ± 1,56%) Control (21,50 ± 1,22%)			

(a) Continued.

Reference	Wound closure analysis	Reepithelialization analysis	Oxidative stress	Granulation tissue fill	Tensile strengths
Lodhi et al., 2011	MAF A (100,00%) 20 days			<i>Hydroxyproline content:</i> MAF A (37,11 ± 1,25%)	
	MAF B (100,00%) 20 days			MAF B (32,86 ± 0,85%)	
	MAF C (100,00%) 18 days	MAF A and B (20 days)		MAF C (42,01 ± 0,82%)	MAF A (603,00 ± 12,01%)
	Control (90,37 ± 2,07%) 20 days	MAF C (18 days) Control (24 days)	?	Control (21,74 ± 1,85%) <i>Protein content</i> MAF A (56,30 ± 0,55%) MAF B (52,50 ± 1,70%) MAF C (83,60 ± 0,72%) Control (47,30 ± 1,72%)	MAF B (635,00 ± 9,68%) MAF C (850,00 ± 11,89%) Control (423,00 ± 10,96%)
Tabandeh et al., 2013	Silibinin 10%: 100% (18 days)			<i>Content N-acetyl glucosamine and n-acetyl galactosamine:</i> silibinin 10 and 20% ↑ compared with the control groups at days 10, 20, and 30	
	Silibinin 20%: 100% (22 days)	?	?	<i>Hydroxyproline and collagen content:</i> silibinin 10 and 20% ↑ compared with the control groups at days 10, 20, and 30	?
	Control: 100% (26 days)				
				<i>Type I collagen</i> APH: 4.25 Control: 3.25 <i>Fibroblast density</i> APH: 2.87 Control: 1.75	
Sonmez et al., 2015	Absorbable polysaccharide haemostat (APH): (94.74 ± 0.02%) 14 days Control: 87.33 ± 0.02% 14 days	?	?		?

(a) Continued.

Reference	Wound closure analysis	Reepithelialization analysis	Oxidative stress	Granulation tissue fill	Tensile strengths
Karakaş et al., 2012	HOT: (80%) 30 days HOTBp: (100%) 30 days Control: (80%) 30 days	?	?	HOT: ↑ fibroblastic and lymphocytes: 5 days HOTBp: ↑ fibroblastic and lymphocytes: 5 days Control: ↑ fibroblastic and lymphocytes: 5 days HOT: ↑ collagen fibrils: 10 days HOTBp: ↑ collagen fibrils: 10 days Control: ↑ collagen fibrils: 10 days	?
Choi et al., 2001	GIGIMIDL2: (98,9%) 8 days Control: (69,5%) 8 days	<i>Epithelialization in 8 days</i> GIGIMIDL2: 98,9% Control: 69,5%	?	<i>EGF receptor</i> GIGIMIDL2 0,5%: (113%) GIGIMIDL2 50%: (220 ± 8%) Control: 100% <i>Fibronectin</i> GIGIMIDL2 0,5%: (294 ± 34%) GIGIMIDL2 50%: (408 ± 80%) Control: 100% <i>Fibronectin receptor</i> GIGIMIDL2 0,5%: (159 ± 11%) GIGIMIDL2 50%: (220 ± 19%) Control: 100%	?
Parente et al., 2011	?	?	?	Number of blood vessels HCF 1 (0/4) DCF 2 (0/13) Control 2 (0/13) Days 4 and 7: presence of fibrin in both groups	?

(a) Continued.

Reference	Wound closure analysis	Reepithelialization analysis	Oxidative stress	Granulation tissue fill	Tensile strengths
	<i>Flabellaria paniculata</i>	<i>Flabellaria paniculata</i> on			
	Chloroform fraction: 0.0	<i>noninfected rat wounds</i>			
Olugbuyiro et al., 2010	Aqueous fraction: 25.0 ± 3.0% (71.4%) 14 days Control: 87.5 ± 7.5%	Chloroform fraction: (14.0 ± 0.0%) Aqueous fraction: (21.5 ± 0.5%) Control: (24.5 ± 0.5%)	?	?	?
	mm ² (%)				mm ² (%)
	Fr.A: 1.60 ± 1.53 (44.4%)				Fr.A: 21.52 ± 1.15 (13.9%)
	Fr.B: 1.59 ± 0.11 (44.8%)				Fr.B: 24.97 ± 3.18 (32.3%)
Süntar et al., 2010	Fr.C: 0.99 ± 0.31 (65.6%) Fr.D: 0.77 ± 0.03 (73.3%) Fr.E: 1.98 ± 0.63 (31.3%) Control: 2.88 ± 0.72 (17.5%)	?	?	?	Fr.C: 25.63 ± 1.43 (35.8%) Fr.D: 26.61 ± 2.05 (40.9%) Fr.E: 22.95 ± 2.73 (21.6%) Control: 18.88 ± 2.67 (16.3%)
	The ginsenoside Rd-treated wounds were significantly smaller than the wounds treated with control Matrigel on days 6 and 9			Ginsenoside Rd ↑ proliferation and migration fibroblasts; ginsenoside Rd at 0.1–10 mM ↑ collagen type I protein and ↓ MMP-1 protein in fibroblasts	
Kim et al., 2013			?	Fraction I increase in hexosamine	Fraction I: 719.33 g ± 0.88
		Fraction I: 9 days		hexosamine	Fraction II: 572.33 g ± 2.46
		Fraction II: 23 days	?	Fractions II and III did not reveal increase in the hexosamine content of granulation tissue	Fraction III: 590.33 g ± 1.87
Chaudhari et al., 2006	?	Fraction III: 20 days			

(a) Continued.

Reference	Wound closure analysis	Reepithelialization analysis	Oxidative stress	Granulation tissue fill	Tensile strengths
Swamy et al., 2006	Embelin: (98.50% ± 1.64) 16 days Control: (85.33% ± 3.66) 16 days	<i>Epithelialization in days</i> Embelin: 18.17 ± 1.47 Control: 20.33 ± 2.66	?	Granulation tissue showed complete healing with more fibroblasts, collagen, and increased number of blood vessels	Embelin: 528.00 g ± 15.85 Control: 374.67 g ± 5564
Hernandes et al., 2010	The 1% ethyl-acetate fraction from <i>Stryphnodendron adstringens</i> did not influence wound contraction	No difference in the length of newly formed epithelium was found between the treated and control wounds	?	?	?
(b)					
Reference	Wound closure analysis	Reepithelialization analysis	Oxidative stress	Granulation tissue fill	Tensile strengths
Sidhu et al., 1999	Arnebin-1 reduced wound width wounds compared with control	Arnebin-1: 7 days Control: only epithelial migration over the dermis	?	The organization of the granulation tissue was more advanced in arnebin-1-treated wounds with thick bundles of well-aligned collagen compared with controls	?
Paramesha et al., 2015	Dehydroabietylamine: (97.78% ± 2.15) 16 days Control: (82.92% ± 1.83) 16 days	<i>Epithelialization in days</i> Dehydroabietylamine: 17.67 ± 2.62 Control: 23.17 ± 1.14	?	<i>Hydroxyproline content (µg/100 g)</i> Dehydroabietylamine: 2106,50 ± 2,62 Control: 1369,67 ± 10,54	Dehydroabietylamine: 425.67 g ± 10.03 Control: 277.00 g ± 9.39

(b) Continued.

Reference	Wound closure analysis	Reepithelialization analysis	Oxidative stress	Granulation tissue fill	Tensile strengths
Nagappan et al., 2012	Mahanine and mahanimbicine: (88.5% ± 2.03 to 93% ± 2.04) 16 days Control: (82.7% ± 2.13) 16 days	Mahanine and mahanimbicine: 18 days Control: 18 days	?	<i>Collagen deposition</i> Mahanine and mahanimbicine: (65.63% ± 0.87 to 67.76% ± 0.85) 21 days and (81.56% ± 1.04 to 88.54% ± 1.34) 28 days Control: (61.84% ± 0.94) 21 days and (78.06% ± 1.22) 28 days	
Qu et al., 2013	Compound I to compound VII: (96.8% ± 1.9 to 87.0% ± 2.6) 16 days Control: (87.2% ± 3.1) 16 days	Compound I and compound V: 18 days Control and other groups: 22 days	?	<i>Hydroxyproline content (mg/g tissue)</i> Compound I to compound VII: 58.4 ± 3.7 to 80.3 ± 4.4 Control: 60.2 ± 4.1	Compound I to compound VII: 431.5 g ± 8.3 to 547.3 g ± 7.9 Control: 436.5 g ± 7.6
Ghosh et al., 2012	Compound I to compound II: (100%) 18 days Control: (100%) 22 days	Compound I: 17.16 ± 0.4 days Compound II: 17.25 ± 0.25 days Control: 22.00 ± 0.1 days	?	Compounds I and II: fibrous connective tissue with strong collagenation Control: fibrosis and more aggregation of macrophages with less collagen fibers	Compound I: 565.10 g ± 3.1 Compound II: 561.12 g ± 3.9 Control: 372.13 g ± 3.23
Mukherjee et al., 2013	Compound I (2,5%): (89.91% ± 0.55) 18 days Compound II (2,5%): (97.89% ± 0.77) 18 days Control: (75.44% ± 0.37) 18 days	Compound I (2,5%): 17.16 ± 0.4 days Compound II (2,5%): 16.01 ± 0.33 days Control: 21.00 ± 0.11 days	?	<i>Hydroxyproline content (mg/g tissue)</i> Compound I (2,5%): 158.23 ± 0.44 Compound II (2,5%): 198.16 ± 0.33 Control: 151.9 ± 2.69	Compound I (2,5%): 538.00 g ± 1.89 Compound II (2,5%): 535.12 g ± 3.59 Control: 322.39 g ± 2.66
Melo et al., 2011	Cramoll 1,4: (100%) 10 days Control: (100%) 12 days	?	?	<i>Crust presence: cramoll 1,4: 13.1 ± 7.02</i> Control: 5.4 ± 3.3 <i>Collagen presence: cramoll 1,4: (higher collagen deposition and annex sprouts) 12 days</i> Control: (matrix poor in collagen fibers) 12 days	?

(b) Continued.

Reference	Wound closure analysis	Reepithelialization analysis	Oxidative stress	Granulation tissue fill	Tensile strengths
Pieters et al., 1995	3',4-0-Dimethylcedrusin: (85%) 15 days Taspine: (75%) 15 days Control: (60%) 15 days	3',4-0-Dimethylcedrusin: ++ (15 days) Taspine: + (15 days) Control: + (15 days)	?	<i>Crust presence</i> 3',4-0-Dimethylcedrusin: after 5 days Taspine: after 5 days Control: after 3 days	?
Alhamed et al., 2009	Gulonic acid γ -lactone: (94.02% \pm 0.20) 16 days Control: (79.53% \pm 0.97) 16 days	<i>Epithelialization in days</i> Gulonic acid γ -lactone: 18.62 \pm 0.21 Control: 22.59 \pm 0.15	?	<i>Hydroxyproline content</i> ($\mu\text{g}/100\text{g}$) Gulonic acid γ -lactone: 780.48 \pm 50.73 Control: 346.15 \pm 14.54 <i>Fibroblast count/high power field</i> $\times 400$ Gulonic acid γ -lactone: 53.26 \pm 2.37 Control: 97.53 \pm 4.26 <i>Blood vessel count/high power field</i> $\times 400$ Gulonic acid γ -lactone: 21.94 \pm 1.15 Control: 11.63 \pm 1.11	Gulonic acid γ -lactone: 561.12 g \pm 5.18 Control: 327.63 g \pm 6.37
Zyuz'kov et al., 2012	Songorine: 100% (9-16 days) Napelline: 100% (9-16 days) Hypaconitine: 100% (9-16 days) 12-Epinapelline N-oxide: 89.93% \pm 5.53 (9-16 days) Mesaconitine: 97.8% \pm 2.2 (9-16 days) Control: 89.72% \pm 4.72 (9-16 days)	Songorine-napelline-hypaconitine Newly formed epithelium by the wound edges represented a cell layer of varying thickness without vertical anisomorphism: 5 days	?	<i>Leukocytic infiltration</i> Songorine: reduction (3 days) Napelline: reduction (3 days) Hypaconitine: reduction (3 days) 12-Epinapelline N-oxide: ?/mesaconitine: ?/control: ? <i>Counts of fibroblasts</i> Songorine: increased (3 days) Napelline: increased (3 days) Hypaconitine: increased (3 days) 12-Epinapelline N-oxide: ?/mesaconitine: ?/control: ?	?

(b) Continued.

Reference	Wound closure analysis	Reepithelialization analysis	Oxidative stress	Granulation tissue fill	Tensile strengths
Singh et al., 2005	Deoxyelephantopin: 98.8% ± 0.35 (16 days) Control: 85.8% ± 0.69 (16 days)	<i>Epithelialization in days</i> Deoxyelephantopin: 14.0 ± 0.26 Control: 20.0 ± 0.86	?	Deoxyelephantopin: ↓ macrophages and ↑ collagen formation Control: ↑ macrophages and ↓ collagen formation	Deoxyelephantopin: 412.0 g ± 11.37 Control: 298.6 g ± 8.48
Sharath et al., 2010	Bacoside-A: 98.18% ± 0.05 (16 days) Control: 85.22% ± 0.02 (16 days)	<i>Epithelialization in days</i> Bacoside-A: 18.30 ± 0.01 Control: 20.20 ± 0.04	?	Bacoside-A: ↑ blood vessels and ↑ collagen formation Control: ↑ inflammatory cells, ↓ blood vessels, and ↓ collagen formation	Bacoside-A: 538.47 g ± 0.14 Control: 380.48 g ± 0.11
Vidya et al., 2012	Entadamide: 92.22% ± 0.05 (16 days) Phaseoloidin: 88.50 ± 0.10 (16 days) Entagenic acid: 96.08% ± 0.04 (16 days) Control: 83.31% ± 1.06 (16 days)	<i>Epithelialization in days</i> Entadamide: 19.92 ± 0.01 Phaseoloidin: 21.16 ± 0.02 Entagenic acid: 18.08 ± 0.01 Control: 24.00 ± 0	?	<i>Hydroxyproline content (μg/100 g)</i> Entadamide: 1891.17 ± 2.75 Phaseoloidin: 1690.33 ± 2.80 Entagenic acid: 2001.33 ± 3.53 Control: 1369.67 ± 10.54	Entadamide: 463.33 g ± 4.48 Phaseoloidin: 450.17 g ± 7.55 Entagenic acid: 549.83 g ± 2.21 Control: 260.83 g ± 14.05




FIGURE 1: Flowchart of the strategy applied to recover preclinical studies according to the PRISMA statement.

3. Results

3.1. Included Studies. From the PubMed and Scopus database, 1008 articles were recovered. 164 duplicated studies and 489 with thematic inadequacy were excluded after reading the title and abstract. After recovery of 329 articles in full text, 303 studies were excluded for not meeting the eligibility criteria. Thus, 26 studies were included in the systematic review. The reference list of all included studies was carefully analyzed to ensure the identification of additional relevant studies. Thus, six studies were additionally identified and recovered,

completing 32 works added to this review. From these studies, 19 studies utilized fractions, 12 studies utilized plant isolates, and 1 study used both fractions and isolates for the treatment of cutaneous wounds (Figure 1).

3.2. Qualitative Analysis. The analyzed studies were conducted in 13 different countries, especially India (40.62%, $n = 13$), followed by Brazil and Turkey (12.5%, $n = 4$ each). The most utilized animal models on the experiments were rats (75%, $n = 24$), followed by mice (12.5%, $n = 4$) and




FIGURE 2: Summary of the studies describing the plants species, families, used parts of each species, toxicity tests, and popular indications.

both (12.5%, $n = 4$). Considering the animal strain, 65.7% were Wistar rats, 17.14% were Sprague Dawley rats, 11.42% were Swiss mice, and 5.71% were Hairless mice. Half of the experimental models used male animals ($n = 16$), 15.62% ($n = 5$) used females, and 18.75% ($n = 6$) used both sex. 15.62% ($n = 5$) of all studies did not report this information. The animals' age ranged from 2 to 5 months for rats and from 8 to 12 weeks for mice; however 71.8% ($n = 23$) of the studies did not relate this information. The weight of rats ranged from 150 to 400 g and the mice weighted between 18 and 40 g, and only 2 studies (6.25%) did not report this data.

More than half of the studies did not describe the popular name of the plant species investigated (59.37%, $n = 19$). The first treatments utilized on the control group were as follows: 25% ($n = 8$) used ointment base (which did not have its formulation described), 15.6% ($n = 5$) used saline solution, 9.4% ($n = 3$) used nitrofurazone, and 6.2% ($n = 2$) utilized distilled water. Only 3.1% ($n = 1$) did not present the treatment for the control group. The other works utilized miconazole and nonionic cream; gentamicin; Matrigel solution; soft paraffin (85%), cetostearyl alcohol (5%), hard paraffin (5%), and wool fat (5%); framycetin ointment; PBS;

sodium alginate; Vaseline; Tween 80; tragacanth; povidone iodine ointment; madecassol and ointment base; chlorocresol BP 0.1% mentioned only once, representing 40.6% of all included studies ($n = 13$). 62.5% ($n = 20$) of the plant species were native and 12.5% ($n = 4$) were exotic and 25% ($n = 8$) of the studies did not describe this characteristic.

Investigated wound area presented a large variation (5 mm^2 to 600 mm^2), and 9.37% ($n = 3$) of the studies did not describe this data. The calculations used to measure the wound area were described in only 59.37% ($n = 19$) of the studies. All the works described the interval in which the wound area was measured, and the most common interval was daily, 31.25% ($n = 10$), followed by measurements taken each 4 days, 28.12% ($n = 9$) (Tables 1(a) and 1(b)). From the 32 species of plants, 23 different families were reported, and the main ones are Asteraceae 18.75% ($n = 6$), Euphorbiaceae 9.37% ($n = 3$), Leguminosae 6.25% ($n = 2$), and Fabaceae 6.25% ($n = 2$), and the other families, Liliaceae, Boraginaceae, Scrophulariaceae, Ranunculaceae, Apiaceae, Myrsinaceae, Mimosae, Malpighiaceae, Tiliaceae, Crassulaceae, Martyniaceae, Rutaceae, Araliaceae, Piperaceae, Solanaceae, Caprifoliaceae, Dipterocarpaceae, Oleaceae, and Combretaceae, were mentioned once and represent 59.37% ($n = 19$) of the included studies. The most used plant structures were the leaves representing 37.5% ($n = 12$), followed by the flowers 12.5% ($n = 4$), bole bark 12.5% ($n = 4$), and seeds 6.25% ($n = 2$). The fruit, the whole plant, and the latex were mentioned once, representing 3.12% ($n = 1$) each. However, 21.87% ($n = 7$) of the studies did not mention this information. Considering the popular indication, healing effects were described in 46.87% ($n = 15$) of the studies, followed by anti-inflammatory effects 34.37% ($n = 11$), treatment of gastrointestinal diseases 28.12% ($n = 9$), burns 18.75% ($n = 6$), and antirheumatic 12.5% ($n = 4$) and ophthalmological diseases 6.25% ($n = 2$). 18.75% ($n = 6$) of the studies did not report the popular indication. Only 33.4% ($n = 11$) of the studies report toxicity tests (Figure 2).

3.3. Bias Analysis. Among the analyzed works, 78.12% presented a title coherent to the text, 90.6% presented abstracts containing the objectives, methods, main results, and conclusions, and 75% presented an introduction with sufficient scientific base. All studies described ethical approval and no work reported a blind controlled study. Most studies (87.5%) related to the therapeutic dose administered (90.62%) reported the route of administration and (96.87%) the treatment duration. The choice of administration route was not justified in any study. Most studies (96.87%) reported the investigated animal strain. The sex and weight were reported in 84.37% and 93.75% of the works, respectively, but only 31.25% provided information about the age of the animals. 59.37% of the studies provided information about the experimental conditions (temperature, humidity, light cycles, feed, and water). A statistical analysis was conducted by all studies, but only 68.75% of the studies specified the data analyzed. 84.37% of the studies reported the number of animals in each group. No study reported mortality or modifications on the experimental protocol by adverse events. A coherent interpretation of the results and direct relationship

between objectives and hypothesis were described in 75% of all included studies (Table S2).

In general, the animals treated with isolates and fractions of plants presented an elevated closure rate of the wound, representing 72.72% of the studies [17, 18, 20, 23–27, 29, 30, 33, 35–46], increase in tissue reepithelialization (30.3%) [15, 18–20, 23, 27, 35, 38, 43], increase of the traction strength on the cicatricle tissue (75.75%) [15, 17–20, 22–25, 27, 31, 33–46], greater content and organization of the extracellular matrix on fast expansion of the granulation tissue (42.42%) [17, 18, 23, 30, 32, 33, 36, 38–40, 42, 44–46], and stimulation of the activity of endogenous antioxidant enzymes (9.09%) [16, 21, 22] (Tables 2(a) and 2(b)).

4. Discussion

The use of plant based strategies is opening a new perspective for the treatment of skin wounds, mainly in developing countries, once it represents a simple, low cost, and affordable therapy [1, 7, 56–58]. There are several studies indicating beneficial effects of herbal medicines in all phases of the healing process. In fact, most of the studies included in this systematic review reported that plant fractions and isolates were able to improve the skin wound healing. Apparently, these medicines were especially favorable in controlling the cutaneous inflammatory and oxidative response and in stimulating the granulation tissue formation, collagen maturation, and reepithelialization.

In this review, we did not include studies testing crude plant extracts, since the chemical characterization of the extracts makes it difficult to determine the herbal components responsible for the effects reported. Even in case of including only studies with murine models, different animal strains were observed. This aspect makes the generalizability of the results difficult, since the biological variability directly influences the response to the treatments. In addition, among the 32 analyzed studies, there were large methodological variation and discrepancies in the measure outcomes. An evident example was the wide variation in wound area and time of wound closure. These considerations are important because they are directly associated with the tensile force experienced by the tissue, which profoundly affect the speed and quality of skin repair [59, 60]. Our findings show that 20% of the studies that utilized fractions neglected the analysis of wound closure, an essential piece of information to assess the ability of any intervention to stimulate the healing process. In addition, the interval between measurements of wound area and the used protocols for the calculations were variable, representing methodological flaws that compromise the study reproduction and generalizability of the findings [61, 62].

Considering that the reepithelialization and organization of the granulation tissue are fundamental aspects to understand how chemical substances act to stimulate wound healing, only 60% of all studies analyzed the reepithelialization rate and 75% evaluated the molecular components of the extracellular matrix, especially collagen. These parameters indicate if the wound closure follows a normal process, in which the newly formed tissue gradually develops drastic structural changes to reconstitute the morphofunctional characteristics

of the intact skin. Works which demonstrated the importance of these analyses assert that the type and quantity of collagen fibers deposited on the tissue can be used as a marker of tissue mechanical resistance [2, 3, 9, 58]. The connective and epithelial tissues form a support structure to promote the correct closure of the wound [57, 63], reducing the chances of opportunistic infections in the wounded area [38, 64]. During the formation of granulation tissue, there is predominance of sulfated molecules which attract water, facilitating the cellular migration, and also serve as a support structure for the first formed collagen (type III collagen) [65]. There are enough evidences that the synthesis and differentiation of cells and matrix components are crucial for a normal wound closure [60]. It is already known that the oxidative stress induces cell damage, lipid, protein, and nucleic acids oxidation [66, 67]. It is recognized that cutaneous trauma increases the tissue oxidative stress in the wounded area [66–69]. Although reactive species are able to activate cell signaling pathways and stimulate cell proliferation, differentiation, and neoangiogenesis, excessive production of these molecules inhibits the healing process, especially by inducing cell death and molecular damage in the extracellular matrix [23, 70, 71]. Thus, there is a notorious importance in analyzing the redox balance during skin repair. However, from all analyzed studies, only 15% investigated the oxidative status. This is a surprising finding, since the antioxidant effect is a pivotal mechanism indicated in several studies to support the applicability of plant extracts in the treatment of tissue damage, including skin wounds [66–69]. Another fundamental result on the cutaneous repair process is the restoration of the biomechanical properties, especially the tensile force of the newly formed tissue, which provides functional estimates on the quality of the healing process [37]. In this review, only 35% of all studies investigating plant fractions evaluated the traction resistance of the scar tissue, aspects investigated in 61.53% of the studies with plants isolates.

In our findings, we see that the majority of the studies used male animals, an aspect potentially associated with the hormonal stability, which is not observed in female animals due to the estrous cycle [72]. The use of rats as the experimental model was higher (75%), aspect potentially related to the large body area needed to perform experimental wounds (1 to 5). Thus, it is possible to construct a larger number of wounds and to use a smaller number of animals in each group. In addition, in rats it is possible to collect enough fragments in order to fully analyze the healing process. Another interesting piece of data was the age of the animals, which presented a large variation (rats, 2 to 8 weeks; mice, 5 to 12 weeks). However, 71.8% of the studies did not report this information, making it difficult to establish a temporal basis to determine the effectivity of the herbal treatments investigated. More than half of the studies (59.37%) did not describe the popular name of the plant species. The large number of works that did not describe important variables such as age of the animals and plant species represents a concerning number, once these characteristics are of great importance to ensure the study reproducibility and to allow the elaboration of broad reports with a critical review of the findings [15]. The orientation cited in the ARRIVE guideline describes the minimum

information that all scientific publications using animals should include. This guide also brings items that help to understand the quality of the writing and potential methodological bias that compromise the quality of the evidence [15]. The work title should refer the readers to a brief summary of the article content, providing keywords and terms that could be researched in electronic databases [73]. Only 78.12% of the studies presented a coherent title, while 90.6% presented abstracts with clear information relative to the objectives, methods, main results, and conclusions. Furthermore, 75% presented introduction with enough scientific base, which can make it harder for the reader to understand the relevance of the study. Another observation made through ARRIVE guide refers to the health conditions of the animals during the experiment. Thus, aspects such as information about environmental conditions (temperature and humidity), mortality, feeding, randomization, and reactions indicative of systemic or local toxicity were neglected in most studies, demonstrating that the report bias is a serious limitation of these preclinical tests that compromise the reliability of the results and the quality of the evidence [74].

5. Conclusions

The current evidence indicates that fractions and isolated molecules from plant extracts stimulate the healing process in cutaneous wounds. Apparently, the main effects of these herbal medicines are associated with the stimulation of collagen synthesis, expansion of the granulation tissue, reepithelialization, modulation of the inflammatory response, and oxidative stress during tissue repair. Together, these effects promote increase of the speed of wound closure and the biomechanical resistance of newly formed tissue. However, the serious methodological flaws and report bias observed in most included studies make the current evidence fragile. Thus, the relevance of fractions and isolated molecules from plant extracts in the treatment of skin wound cannot be accurately determined. Considering these limitations, it seems impossible to use these evidences to construct a rational basis that supports clinical studies. Therefore, there is an urgent need to improve research reports in experimental studies with herbal medicines in murine models of skin wound healing. This task requires a collective effort of authors, journal editors, reviewers, and financial organisms, to ensure the reproducibility, reliability, and generalizability of the evidence, fundamental elements to determine to what extent herbal medicines are promising in the treatment of skin wounds.

Competing Interests

The authors declare that there are no competing interests regarding the publication of this paper.

Acknowledgments

This work received financial support from the Brazilian agency Fundação de Amparo à Pesquisa do Estado de Minas Gerais (FAPEMIG) (FAPEMIG Process: APQ 00685-14).

References

- [1] R. Bahramsoltani, M. H. Farzaei, and R. Rahimi, "Medicinal plants and their natural components as future drugs for the treatment of burn wounds: an integrative review," *Archives of Dermatological Research*, vol. 306, no. 7, pp. 601–617, 2014.
- [2] J. Nazaruk and A. Galicka, "The influence of selected flavonoids from the leaves of *Cirsium palustre* (L.) Scop. on collagen expression in human skin fibroblasts," *Phytotherapy Research*, vol. 28, no. 9, pp. 1399–1405, 2014.
- [3] R. V. Gonçalves, R. D. Novaes, S. L. P. Matta, G. P. Benevides, F. R. Faria, and M. V. M. Pinto, "Comparative study of the effects of gallium-aluminum-arsenide laser photobiomodulation and healing oil on skin wounds in wistar rats: a histomorphometric study," *Photomedicine and Laser Surgery*, vol. 28, no. 5, pp. 597–602, 2010.
- [4] L. G. Bowden, P. K. Maini, D. E. Moulton et al., "An ordinary differential equation model for full thickness wounds and the effects of diabetes," *Journal of Theoretical Biology*, vol. 361, pp. 87–100, 2014.
- [5] C.-H. Lee, S.-H. Chang, W.-J. Chen et al., "Augmentation of diabetic wound healing and enhancement of collagen content using nanofibrous glucophage-loaded collagen/PLGA scaffold membranes," *Journal of Colloid and Interface Science*, vol. 439, pp. 88–97, 2015.
- [6] P. Mikaili, M. Moloudizargari, and S. Aghajanshakeri, "Treatment with topical nitroglycerine may promote the healing process of diabetic foot ulcers," *Medical Hypotheses*, vol. 83, no. 2, pp. 172–174, 2014.
- [7] Y. Q. Tan, K. Y. Wang, N. Wang, G. Li, and D. Liu, "Ectopic expression of human acidic fibroblast growth factor 1 in the medicinal plant, *Salvia miltiorrhiza*, accelerates the healing of burn wounds," *BMC Biotechnology*, vol. 14, no. 1, article 74, pp. 1–10, 2014.
- [8] A. D. S. Rosa, L. G. Bandeira, A. Monte-Alto-Costa, and B. Romana-Souza, "Supplementation with olive oil, but not fish oil, improves cutaneous wound healing in stressed mice," *Wound Repair and Regeneration*, vol. 22, no. 4, pp. 537–547, 2014.
- [9] Z. Xie, C. B. Paras, H. Weng et al., "Dual growth factor releasing multi-functional nanofibers for wound healing," *Acta Biomaterialia*, vol. 9, no. 12, pp. 9351–9359, 2013.
- [10] F. G. Bueno, G. P. Panizzon, E. V. S. D. L. Mello et al., "Hydrolyzable tannins from hydroalcoholic extract from *Poincianella pluviosa* stem bark and its wound-healing properties: phytochemical investigations and influence on in vitro cell physiology of human keratinocytes and dermal fibroblasts," *Fitoterapia*, vol. 99, pp. 252–260, 2014.
- [11] L. Abenavoli, R. Capasso, N. Milic, and F. Capasso, "Milk thistle in liver diseases: past, present, future," *Phytotherapy Research*, vol. 24, no. 10, pp. 1423–1432, 2010.
- [12] A. Oryan, A. T. Naeini, B. Nikahval, and E. Gorjlan, "Effects of aqueous extract of Aloe vera on experimental cutaneous wound healing in rat," *Veterinarski Arhiv*, vol. 80, no. 4, pp. 509–522, 2010.
- [13] A. P. Chaturvedi, M. Kumar, and Y. B. Tripathi, "Efficacy of *Jasminum grandiflorum* L. leaf extract on dermal wound healing in rats," *International Wound Journal*, vol. 10, no. 6, pp. 675–682, 2013.
- [14] N. Pazyar, R. Yaghoobi, E. Rafiee, A. Mehrabian, and A. Feily, "Skin wound healing and phytomedicine: a review," *Skin Pharmacology and Physiology*, vol. 27, no. 6, pp. 303–310, 2014.
- [15] C. Kilkenny, W. J. Browne, I. C. Cuthill, M. Emerson, and D. G. Altman, "Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research," *PLoS Biology*, vol. 8, no. 6, 2010.
- [16] Y. Yun, K. Kim, I. Choi, and S.-G. Ko, "Topical herbal application in the management of atopic dermatitis: a review of animal studies," *Mediators of Inflammation*, vol. 2014, Article ID 752103, 8 pages, 2014.
- [17] A. Shukla, A. M. Rasik, and B. N. Dhawan, "Asiaticoside-induced elevation of antioxidant levels in healing wounds," *Phytotherapy Research*, vol. 13, no. 1, pp. 50–54, 1999.
- [18] A. Muralidhar, K. S. Babu, T. R. Sankar, P. Reddanna, and J. Latha, "Evaluation of wound healing properties of bioactive fractions from the extract of *Butea monosperma* (lam) stem bark," *International Journal of Phytomedicine*, vol. 3, no. 1, pp. 41–49, 2011.
- [19] I. Süntar, E. K. Akkol, H. Keles, E. Yesilada, and S. D. Sarker, "Exploration of the wound healing potential of *Helichrysum graveolens* (Bieb.) Sweet: isolation of apigenin as an active component," *Journal of Ethnopharmacology*, vol. 149, no. 1, pp. 103–110, 2013.
- [20] A. Mekonnen, T. Sidamo, K. Asres, and E. Engidawork, "In vivo wound healing activity and phytochemical screening of the crude extract and various fractions of *Kalanchoe petitiiana* A. Rich (Crassulaceae) leaves in mice," *Journal of Ethnopharmacology*, vol. 145, no. 2, pp. 638–646, 2013.
- [21] L. Pieters, T. De Bruyne, B. Van Poel et al., "In vivo wound healing activity of Dragon's blood (*Croton* spp.), a traditional South American drug, and its constituents," *Phytomedicine*, vol. 2, no. 1, pp. 17–22, 1995.
- [22] L. G. Korkina, E. V. M. Chik, M. V. Suprun et al., "Molecular mechanisms underlying wound healing and anti-inflammatory properties of naturally occurring biotechnologically produced phenylpropanoid glycosides," *Cellular and Molecular Biology*, vol. 53, no. 5, pp. 84–91, 2007.
- [23] P. Bigoniya, S. Agrawal, and N. K. Verma, "Potential wound healing activity of *Euphorbia hirta* Linn total flavonoid fraction," *International Journal of Pharmaceutical Sciences Review and Research*, vol. 22, no. 2, pp. 149–156, 2013.
- [24] S. Lodhi and A. K. Singhai, "Preliminary pharmacological evaluation of *Martynia annua* Linn leaves for wound healing," *Asian Pacific Journal of Tropical Biomedicine*, vol. 1, no. 6, pp. 421–427, 2011.
- [25] M. R. Tabandeh, A. Oryan, A. M. Alipour, and A. T. Naeini, "Silibinin regulates matrix metalloproteinase 3 (stromelysin1) gene expression, hexoseamines and collagen production during rat skin wound healing," *Phytotherapy Research*, vol. 27, no. 8, pp. 1149–1153, 2013.
- [26] E. Sonmez, K. A. Turkdogan, C. Civelek et al., "The efficacy of absorbable polysaccharide haemostats in wound healing," *Blood Coagulation & Fibrinolysis*, vol. 26, no. 1, pp. 50–53, 2015.
- [27] F. P. Karakaş, A. Karakaş, Ç. Boran, A. U. Türker, F. N. Yaşın, and E. Bilensoy, "The evaluation of topical administration of *Bellis perennis* fraction on circular excision wound healing in Wistar albino rats," *Pharmaceutical Biology*, vol. 50, no. 8, pp. 1031–1037, 2012.
- [28] S.-W. Choi, B.-W. Son, Y.-S. Son, Y.-I. Park, S.-K. Lee, and M.-H. Chung, "The wound-healing effect of a glycoprotein fraction isolated from aloe vera," *British Journal of Dermatology*, vol. 145, no. 4, pp. 535–545, 2001.
- [29] L. M. L. Parente, R. D. S. L. Júnior, L. M. F. Tresvenzol, M. C. Vinaud, J. R. De Paula, and N. M. Paulo, "Wound healing

- and anti-inflammatory effect in animal models of *Calendula officinalis* L. growing in Brazil," *Evidence-Based Complementary and Alternative Medicine*, vol. 2012, Article ID 375671, 7 pages, 2012.
- [30] J. A. O. Olugbuyiro, K. A. Abo, and O. O. Leigh, "Wound healing effect of *Flabellaria paniculata* leaf extracts," *Journal of Ethnopharmacology*, vol. 127, no. 3, pp. 786–788, 2010.
- [31] I. P. Süntar, E. K. Akkol, F. N. Yalçın, U. Koca, H. Keleş, and E. Yesilada, "Wound healing potential of *Sambucus ebulus* L. leaves and isolation of an active component, quercetin 3-O-glucoside," *Journal of Ethnopharmacology*, vol. 129, no. 1, pp. 106–114, 2010.
- [32] W.-K. Kim, S.-Y. Song, W. K. Oh et al., "Wound-healing effect of ginsenoside Rd from leaves of *Panax ginseng* via cyclic AMP-dependent protein kinase pathway," *European Journal of Pharmacology*, vol. 702, no. 1–3, pp. 285–293, 2013.
- [33] M. Chaudhari and S. Mengi, "Evaluation of phytoconstituents of *Terminalia arjuna* for wound healing activity in rats," *Phytotherapy Research*, vol. 20, no. 9, pp. 799–805, 2006.
- [34] H. M. Kumara Swamy, V. Krishna, K. Shankarmurthy et al., "Wound healing activity of embelin isolated from the ethanol extract of leaves of *Embelia ribes* Burm.," *Journal of Ethnopharmacology*, vol. 109, no. 3, pp. 529–534, 2007.
- [35] L. Hernandez, L. M. da Silva Pereira, F. Palazzo, and J. C. P. de Mello, "Wound-healing evaluation of ointment from *Stryphnodendron adstringens* (barbatimão) in rat skin," *Brazilian Journal of Pharmaceutical Sciences*, vol. 46, no. 3, pp. 431–436, 2010.
- [36] G. S. Sidhu, A. K. Singh, and K. K. Banaudha, "Accelerates normal and hydrocortisone-induced impaired wound healing," *The Journal of Investigative Dermatology*, vol. 113, no. 5, pp. 773–781, 1999.
- [37] M. Paramesha, C. K. Ramesh, V. Krishna, H. M. Kumar Swamy, S. J. Aditya Rao, and J. Hoskerri, "Effect of dehydroabietylamine in angiogenesis and GSK3- β inhibition during wound healing activity in rats," *Medicinal Chemistry Research*, vol. 24, no. 1, pp. 295–303, 2015.
- [38] T. Nagappan, T. C. Segaran, M. E. A. Wahid, P. Ramasamy, and C. S. Vairappan, "Efficacy of carbazole alkaloids, essential oil and extract of *Murraya koenigii* in enhancing subcutaneous wound healing in rats," *Molecules*, vol. 17, no. 12, pp. 14449–14463, 2012.
- [39] X. Qu, Y. Diao, Z. Zhang, S. Wang, and Y. Jia, "Evaluation of anti-bacterial and wound healing activity of the fruits of *Amorpha fruticosa* L.," *African Journal of Traditional, Complementary, and Alternative Medicines*, vol. 10, no. 3, pp. 458–468, 2013.
- [40] S. Ghosh, A. Samanta, N. B. Mandal, S. Bannerjee, and D. Chattopadhyay, "Evaluation of the wound healing activity of methanol extract of *Pedilanthus tithymaloides* (L.) Poit leaf and its isolated active constituents in topical formulation," *Journal of Ethnopharmacology*, vol. 142, no. 3, pp. 714–722, 2012.
- [41] H. Mukherjee, D. Ojha, Y. P. Bharitkar et al., "Evaluation of the wound healing activity of *Shorea robusta*, an Indian ethnomedicine, and its isolated constituent(s) in topical formulation," *Journal of Ethnopharmacology*, vol. 149, no. 1, pp. 335–343, 2013.
- [42] C. M. L. D. Melo, C. S. Porto, M. R. M. Júnior et al., "Healing activity induced by Cramoll I,4 lectin in healthy and immunocompromised mice," *International Journal of Pharmaceutics*, vol. 408, no. 1–2, pp. 113–119, 2011.
- [43] B. M. K. Ahamed, V. Krishna, and K. H. Malleshappa, "In vivo wound healing activity of the methanolic extract and its isolated constituent, gulonic acid γ -lactone, obtained from *Grewia tiliaefolia*," *Planta Medica*, vol. 75, no. 5, pp. 478–482, 2009.
- [44] G. N. Zyuz'kov, A. V. Krapivin, Y. V. Nesterova et al., "Mechanisms of regenerative effects of Baikal aconite diterpene alkaloids," *Bulletin of Experimental Biology and Medicine*, vol. 153, no. 6, pp. 847–851, 2012.
- [45] S. D. J. Singh, V. Krishna, K. L. Mankani, B. K. Manjunatha, S. M. Vidya, and Y. N. Manohara, "Wound healing activity of the leaf extracts and deoxyelephantopin isolated from *Elephantopus scaber* Linn.," *Indian Journal of Pharmacology*, vol. 37, no. 4, pp. 238–242, 2005.
- [46] R. Sharath, B. G. Harish, V. Krishna, B. N. Sathyanarayana, and H. M. Kumara Swamy, "Wound healing and protease inhibition activity of bacoside-A, isolated from *Bacopa monnieri* Wettst.," *Phytotherapy Research*, vol. 24, no. 8, pp. 1217–1222, 2010.
- [47] M. D. Martins, M. M. Marques, S. K. Bussadori et al., "Comparative analysis between *Chamomilla recutita* and corticosteroids on wound healing. An *in vitro* and *in vivo* study," *Phytotherapy Research*, vol. 23, no. 2, pp. 274–278, 2009.
- [48] B. K. Manjunatha, S. M. Vidya, V. Krishna, K. L. Mankani, S. D. Jagadeesh Singh, and Y. N. Manohara, "Comparative evaluation of wound healing potency of *Vitex trifolia* L. and *Vitex altissima* L.," *Phytotherapy Research*, vol. 21, no. 5, pp. 457–461, 2007.
- [49] A. Roy and S. Saraf, "Limonoids: overview of significant bioactive triterpenes distributed in plants kingdom," *Biological and Pharmaceutical Bulletin*, vol. 29, no. 2, pp. 191–201, 2006.
- [50] H. A. Miot, R. F. Batistella, K. D. A. Batista et al., "Comparative study of the topical effectiveness of the Andiroba oil (*Carapa guianensis*) and DEET 50% as repellent for *Aedes* sp.," *Revista do Instituto de Medicina Tropical de São Paulo*, vol. 46, no. 5, pp. 253–256, 2004.
- [51] H. P. Huemer, "Possible immunosuppressive effects of drug exposure and environmental and nutritional effects on infection and vaccination," *Mediators of Inflammation*, vol. 2015, Article ID 349176, 7 pages, 2015.
- [52] S. Shetty, S. Udupa, and L. Udupa, "Evaluation of antioxidant and wound healing effects of alcoholic and aqueous extract of *Ocimum sanctum* Linn in rats," *Evidence-Based Complementary and Alternative Medicine*, vol. 5, no. 1, pp. 95–101, 2008.
- [53] J. Parry, L. Su, J. Moore et al., "Chemical compositions, antioxidant capacities, and antiproliferative activities of selected fruit seed flours," *Journal of Agricultural and Food Chemistry*, vol. 54, no. 11, pp. 3773–3778, 2006.
- [54] J. Shi, J. Yu, J. E. Pohorly, and Y. Kakuda, "Polyphenolics in grape seeds—biochemistry and functionality," *Journal of Medicinal Food*, vol. 6, no. 4, pp. 291–299, 2003.
- [55] C. R. Hooijmans, A. Tillema, M. Leenaars, and M. Ritskes-Hoitinga, "Enhancing search efficiency by means of a search filter for finding all studies on animal experimentation in PubMed," *Laboratory Animals*, vol. 44, no. 3, pp. 170–175, 2010.
- [56] X.-B. Wu, X.-Q. Luo, S.-Y. Gu, and J.-H. Xu, "The effects of *Polygonum cuspidatum* extract on wound healing in rats," *Journal of Ethnopharmacology*, vol. 141, no. 3, pp. 934–937, 2012.
- [57] R. V. Gonçalves, S. L. P. da Matta, R. D. Novaes, J. P. V. Leite, M. D. C. G. Peluzio, and E. F. Vilela, "Bark extract of *Bathysa cuspidata* in the treatment of liver injury induced by carbon tetrachloride in rats," *Brazilian Archives of Biology and Technology*, vol. 57, no. 4, pp. 504–513, 2014.
- [58] M. M. Sarandy, R. D. Novaes, S. L. P. Da Matta et al., "Ointment of *Brassica oleracea* var. *capitata* matures the extracellular

- matrix in skin wounds of wistar rats,” *Evidence-Based Complementary and Alternative Medicine*, vol. 2015, Article ID 919342, 9 pages, 2015.
- [59] S. A. Park, V. K. Raghunathan, N. M. Shah et al., “PDGF-BB does not accelerate healing in diabetic mice with splinted skin wounds,” *PLoS ONE*, vol. 9, no. 8, Article ID e104447, 2014.
- [60] J. Zhu, A. Yu, B. Qi, Z. Li, and X. Hu, “Effects of negative pressure wound therapy on mesenchymal stem cells proliferation and osteogenic differentiation in a fibrin matrix,” *PLoS ONE*, vol. 9, no. 9, Article ID e107339, 2014.
- [61] L. Yonehiro, G. Bureson, and V. Sauer, “Use of a new acellular dermal matrix for treatment of nonhealing wounds in the lower extremities of patients with diabetes,” *Wounds*, vol. 26, no. 5, pp. E39–E47, 2014.
- [62] I. Simera and D. G. Altman, “Writing a research article that is ‘fit for purpose’: EQUATOR Network and reporting guideline,” *Evidence-Based Medicine*, vol. 14, no. 5, pp. 132–134, 2009.
- [63] M. Xavier, D. R. David, R. A. De Souza et al., “Anti-inflammatory effects of low-level light emitting diode therapy on achilles tendinitis in rats,” *Lasers in Surgery and Medicine*, vol. 42, no. 6, pp. 553–558, 2010.
- [64] G. Lerman, M. Sharon, R. Leibowitz-Amit, Y. Sidi, D. Avni, and F. Martelli, “The crosstalk between IL-22 signaling and miR-197 in human keratinocytes,” *PLoS ONE*, vol. 9, no. 9, Article ID e107467, pp. 1–13, 2014.
- [65] T. L. Assis De Brito, A. Monte-Alto-Costa, and B. Romana-Souza, “Propranolol impairs the closure of pressure ulcers in mice,” *Life Sciences*, vol. 100, no. 2, pp. 138–146, 2014.
- [66] P. C. L. Silveira, L. A. Silva, T. Tuon, T. P. Freitas, E. L. Streck, and R. A. Pinho, “Effects of low-level laser therapy on epidermal oxidative response induced by wound healing,” *Revista Brasileira de Fisioterapia*, vol. 13, no. 4, pp. 281–287, 2009.
- [67] N. Servetto, D. Cremonozzi, J. C. Simes et al., “Evaluation of inflammatory biomarkers associated with oxidative stress and histological assessment of low-level laser therapy in experimental myopathy,” *Lasers in Surgery and Medicine*, vol. 42, no. 6, pp. 577–583, 2010.
- [68] S. Guo and L. A. DiPietro, “Factors affecting wound healing,” *Journal of Dental Research*, vol. 89, no. 3, pp. 219–229, 2010.
- [69] M. G. Scioli, P. L. Giudice, A. Bielli et al., “Propionyl-L-carnitine enhances wound healing and counteracts microvascular endothelial cell dysfunction,” *PLoS ONE*, vol. 10, no. 10, Article ID e0140697, pp. 1–20, 2015.
- [70] W. Dröge, “Free radicals in the physiological control of cell function,” *Physiological Reviews*, vol. 82, no. 1, pp. 47–95, 2002.
- [71] M. Ewertowska, P. Ł. Mikołajczak, I. Okulicz-kozaryn, B. Stachecki, M. Murias, and J. Jodynis-Liebert, “Different response of antioxidant defense system to acamprosate in ethanol preferring and non-preferring rats,” *Acta Poloniae Pharmaceutica—Drug Research*, vol. 72, no. 3, pp. 439–445, 2015.
- [72] P. V. Peplow, T.-Y. Chung, and G. D. Baxter, “Laser photobiomodulation of proliferation of cells in culture: a review of human and animal studies,” *Photomedicine and Laser Surgery*, vol. 28, supplement 1, pp. S3–S40, 2010.
- [73] C. W. Fox and C. S. Burns, “The relationship between manuscript title structure and success: editorial decisions and citation performance for an ecological journal,” *Ecology and Evolution*, vol. 5, no. 10, pp. 1970–1980, 2015.
- [74] R. F. Sampaio and M. C. Mancini, “Estudos de revisão sistemática: um guia para síntese criteriosa da evidência científica,” *Revista Brasileira de Fisioterapia*, vol. 11, no. 1, pp. 83–89, 2007.



Hindawi
Submit your manuscripts at
<http://www.hindawi.com>

